TR-1: Standard form notification of major holdings

Thalia Therapeutics

23/04/2025 14:32

RNS Number : 9059F

N4 Pharma PLC

23 April 2025

 

TR-1: Standard form for notification of major holdings

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:
N4 Pharma PLC
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)
Non-UK issuer
2. Reason for the notification(please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
X
Other (please specify)iii:
3. Details of person subject to the notification obligationiv
Name
NIGEL JAMES THEOBALD
City and country of registered office (if applicable)
UK
4. Full name of shareholder(s)(if different from 3.)v
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reachedvi:
23 APRIL 2025
6. Date on which issuer notified (DD/MM/YYYY):
23 APRIL 2025
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A)
% ofvoting rights throughfinancial instruments
 (total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B)
Total number of voting rights of issuervii
Resulting situation on the date on which threshold was crossed or reached
2.04%
2.04%
832,280,349
Position of previous notification (if
applicable)
4.30%
4.30%


 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type of
 shares
ISIN code (if possible)
Number of voting rightsix
% of voting rights
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
GB00BYW8QM32
16,981,319
0
2.04
0
SUBTOTAL 8. A
16,981,319
2.04
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument
Expiration
 datex
Exercise/
 Conversion Periodxi
Number of voting rights that may be acquired if the instrument is
exercised/converted.
% of voting rights
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument
Expiration
 datex
Exercise/
 Conversion Periodxi
Physical or cash
settlementxii
Number of voting rights
% of voting rights
SUBTOTAL 8.B.2


 

9. Information in relation to the person subject to the notification obligation(please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii
X
Fullchain of controlled undertakings through which the voting rights and/or the
 financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv(please add additional rows as necessary)
Namexv
% of voting rights if it equals or is higher than the notifiable threshold
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold
Total of both if it equals or is higher than the notifiable threshold
10.In case of proxy voting, please identify:
Name of the proxy holder
N/A
The number and % of voting rights held
N/A
The date until which the voting rights will be held
N/A
11. Additional informationxvi

 The Company's issued share capital increased following a Placing announced on 7 June.


 

Place of completion
UK
Date of completion
23 APRIL 2025

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
HOLSESFDDEISEDL